Drug Profile
Risperidone controlled release - DURECT
Alternative Names: Relday; Risperidone sustained release; SABER™ risperidone; ZX-003Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Fluorinated hydrocarbons; Isoxazoles; Mood stabilisers; Piperidines; Pyrimidinones; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bipolar disorders; Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia in USA (SC, Controlled release)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bipolar-disorders in USA (SC, Controlled release)
- 30 Sep 2015 Pharmacokinetics and adverse events data from a phase I trial in Schizophrenia released by Zogenix